These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23176647)

  • 21. Cost of vaccinating refugees overseas versus after arrival in the United States, 2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Mar; 57(9):229-32. PubMed ID: 18322445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using transfer pricing in decision making.
    Tarantino D
    Physician Exec; 2003; 29(2):57-8. PubMed ID: 12685273
    [No Abstract]   [Full Text] [Related]  

  • 23. Public support in the United States for global equity in vaccine pricing.
    Chan Y; Datt G; Islam A; Rai B; Wang LC
    Sci Rep; 2022 May; 12(1):8960. PubMed ID: 35624169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National vaccine injury compensation program: calculation of average cost of a health insurance policy. Final rule.
    Health Resources and Services Administration (HRSA), HHS
    Fed Regist; 2007 Jul; 72(128):36610-2. PubMed ID: 17674490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1325-31. PubMed ID: 19047253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine finance resources for physicians.
    Sobczyk E
    Pediatrics; 2009 Dec; 124 Suppl 5():S573-6. PubMed ID: 19948594
    [No Abstract]   [Full Text] [Related]  

  • 28. Pricing: Part I. Three menu pricing systems.
    Hosp Food Nutr Focus; 1986 Dec; 3(4):1, 4-5. PubMed ID: 10279686
    [No Abstract]   [Full Text] [Related]  

  • 29. How important are airfreight rates and vaccine packaging in cost-saving efforts for the Expanded Programme on Immunization?
    Schreuder B; Arentsen H; Matosse M
    Bull World Health Organ; 1997; 75(4):315-21. PubMed ID: 9342890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The United States pediatric vaccine stockpile program.
    Lane KS; Chu SY; Santoli JM
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S125-9. PubMed ID: 16447134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria.
    Plebanski M; Lopez E; Proudfoot O; Cooke BM; Itzstein Mv; Coppel RL
    Methods; 2006 Sep; 40(1):77-85. PubMed ID: 16997716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to "Modeling the national pediatric vaccine stockpile: supply shortages, health impacts and cost consequences".
    Proano RA; Jacobson SH; Jokela JA
    Vaccine; 2011 Jan; 29(4):615; author reply 616. PubMed ID: 21094271
    [No Abstract]   [Full Text] [Related]  

  • 34. Pricing hospital services. Developing a cost base for pricing.
    Johnson KF
    Top Health Care Financ; 1987; 14(1):16-25. PubMed ID: 3672509
    [No Abstract]   [Full Text] [Related]  

  • 35. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming economic barriers to the optimal use of vaccines.
    Lieu TA; McGuire TG; Hinman AR
    Health Aff (Millwood); 2005; 24(3):666-79. PubMed ID: 15886158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pricing products and services, Part one: Determination of production cost.
    Michaels KV
    J Biol Photogr; 1995 Jan; 63(1):15-21. PubMed ID: 7890584
    [No Abstract]   [Full Text] [Related]  

  • 38. Vaccine financing in the United States: an emerging crisis.
    Lee GM; Lieu TA
    Arch Pediatr Adolesc Med; 2009 May; 163(5):485-7. PubMed ID: 19414698
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug development costs when financial risk is measured using the Fama-French three-factor model.
    Vernon JA; Golec JH; Dimasi JA
    Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using cost-per-procedure statistics to control costs.
    Golan D
    OR Manager; 1987 May; 3(5):4-5. PubMed ID: 10282414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.